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Epibranchialic placodes are relatively simple model systems for investigating the control of
sensory neurogenesis. The ophthalmic trigeminal (opV) placode, for which the earliest speciﬁc marker is the
paired domain homeodomain transcription factor Pax3, forms cutaneous sensory neurons in the ophthalmic
lobe of the trigeminal ganglion. We previously showed that Pax3 expression in avian opV placode cells
correlates with speciﬁcation and commitment to a Pax3+, cutaneous sensory neuron fate. Pax3 can act as a
transcriptional activator or repressor, depending on the cellular context. We show using mouse Splotch2H
mutants that Pax3 is necessary for the normal neuronal differentiation of opV placode cells. Using an
electroporation construct encoding a Pax3–Engrailed fusion protein, which represses Pax3 target genes, we
show that activation of Pax3 target genes is required cell-autonomously within chick opV placode cells for
expression of the opV placode markers FGFR4 and Ngn2, maintenance of the preplacodal marker Eya2,
expression of Pax3 itself (suggesting that Pax3 autoregulates), neuronal differentiation and delamination.
Mis-expression of Pax3 in head ectoderm is sufﬁcient to induce FGFR4 and Ngn2 expression, but neurons do
not differentiate, suggesting that additional signals are necessary to enable Pax3+ cells to differentiate as
neurons. Mis-expression of Pax3 in the Pax2+ otic and epibranchial placodes also downregulates Pax2 and
disrupts otic vesicle closure, suggesting that Pax3 is sufﬁcient to alter the identity of these cells. Overall, our
results suggest that activation of Pax3 target genes is necessary but not sufﬁcient for neurogenesis in the opV
placode.
© 2008 Elsevier Inc. All rights reserved.Introduction
Vertebrate cranial placodes are bilateral patches of thickened head
ectoderm that form the paired peripheral sense organs (olfactory
epithelia, inner ears, lateral line system), the eye lenses, and a wide
variety of sensory neurons in cranial sensory ganglia, as well as the
endocrine adenohypophysis (reviewed in Baker and Bronner-Fraser,
2001; Schlosser, 2006). They provide a relatively simple, accessible set of
model systems in which to investigate the control of sensory neuroge-
nesis and, ultimately, the generation of different neuronal subtypes.
Cranial placodes originate from a “preplacodal region” at the border
between the prospective anterior neural plate and epidermis, cha-
racterised by expression of speciﬁc members of the Six and Eya families
of transcription factors/co-factors (reviewed in Baker and Bronner-
Fraser, 2001; Rebay et al., 2005; Schlosser, 2006; Streit, 2007). Paired0.
k), cvhb1@cam.ac.uk
l rights reserved.domain transcription factors of the Pax family, which can act in complex
regulatory networks with Six, Eya and Dach (reviewed in Pappu and
Mardon, 2004; Schlosser, 2006; Streit, 2007), are also expressed in
different subsets of cranial placodes: Pax6 in the olfactory and lens
placodes; Pax3 in the ophthalmic trigeminal placode; Pax2 and Pax8 in
the otic and epibranchial placodes (reviewed in Baker and Bronner-
Fraser, 2001; Schlosser, 2006), leading to the suggestion that Pax genes
may be important for aspects of individual placode identity (Baker and
Bronner-Fraser, 2000, 2001; Streit, 2004).
Here, we investigate the role of Pax3 in the development of the
ophthalmic trigeminal (opV) placode, which forms cutaneous sensory
neurons in the ophthalmic lobe of the trigeminal ganglion. In the chick,
Pax3 is the earliest speciﬁc marker for the chick opV placode, being
broadly expressed from the 7–8 somite-stage in caudal midbrain/
rostral hindbrain-level ectoderm that is fated to form opV placode-
derived neurons (Stark et al., 1997; Baker et al., 1999; Xu et al., 2008).
Pax3 is expressed in the opV placode in all vertebrates analysed (Stark
et al., 1997; Schlosser and Ahrens, 2004; O'Neill et al., 2007). Using
explant culture and heterotopic grafting experiments, we previously
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with commitment to a Pax3+ cutaneous sensory neuron fate (Baker
et al.,1999, 2002; Baker and Bronner-Fraser, 2000), but the precise role
of Pax3 in opV placode development was unclear.
Pax3 has a paired domain, a paired-type homeodomain, and a C-
terminal transactivation domain; it generally acts as a transcriptional
activator during development (Relaix et al., 2003), though it can
repress some target genes (e.g. Kioussi et al., 1995; Kwang et al., 2002).
Homozygous and heterozygous Pax3 mutant phenotypes in Splotch
mice show that Pax3 is required in different cells for functions as
diverse as migration, differentiation, and survival (reviewed in
Machado et al., 2001; Chi and Epstein, 2002). Heterozygous Splotch
mutants are viable, with patchy pigmentation due to defective
development of neural crest-derived melanocytes, while homozygous
Splotch mutations are mid-gestation lethal with defects in neural tube
closure, somite derivatives, limb muscles and trunk neural crest cell
migration (Auerbach, 1954; Epstein et al., 1991; Epstein et al., 1993;
Schubert et al., 2001). Pax3 has a wide variety of developmental roles,
being required for the delamination and migration of hypaxial and
limb muscle precursor cells (reviewed in Buckingham and Relaix,
2007), for the migration of trunk neural crest cells (Serbedzija and
McMahon, 1997; Mansouri et al., 2001), for the differentiation of
muscle cells (Tajbakhsh et al., 1997; Relaix et al., 2003; Bajard et al.,
2006) and neural crest-derived melanocytes (Watanabe et al., 1998;
Lang and Epstein, 2003; Lang et al., 2005), and for cell survival in the
somites (Borycki et al., 1999).
The ophthalmic nerve in Splotch embryos is missing or reduced at
embryonic day 12.5 (Tremblay et al., 1995), suggesting a role for Pax3
in development of the ophthalmic lobe of the trigeminal ganglion,
from which the ophthalmic nerve projects. However, the ophthalmic
lobe contains not only Pax3+ opV placode-derived neurons, but also
neural crest-derived neurons which originate from Pax3+ neural crest
precursor cells (Baker et al., 2002), while the opV placode is itself
induced by a signal(s) from the Pax3+ dorsal neural tube (Stark et al.,
1997; Baker et al., 1999). Hence, it is unclear which of these Pax3+ cell
populations requires Pax3 function to enable proper formation of the
ophthalmic nerve. Here, by analysing trigeminal ganglion develop-
ment in Splotch2H embryos, and by using in ovo electroporation to
manipulate Pax3 function speciﬁcally in surface ectoderm, we show
that Pax3 is necessary but not sufﬁcient for neurogenesis in the opV
placode.
Materials and methods
Mouse embryos
Sp2Hmiceweremaintained as a random-bred colony, and genotyped
by PCR using primers to Pax3 (Epstein et al., 1991). Mice were killed by
cervical dislocation and embryos dissected from theuterus inDulbecco's
Modiﬁed Eagle's Medium (Invitrogen), rinsed in diethylpyrocarbonate
(DEPC)-treated phosphate-buffered saline (PBS) and ﬁxed in cold 4%
paraformaldehyde in DEPC-PBS. After extensive washing in cold DEPC-
treated PBS, they were dehydrated into 100% methanol and stored at
−20 °C. Embryos were genotyped by PCR using primers to Pax3 (Epstein
et al., 1991) on DNA extracted from tail samples.
In situ hybridisation
Whole-mount in situ hybridisation on mouse embryos was
performed as in O'Neill et al. (2007) with minor modiﬁcations; a
detailed protocol is available on request. In situ hybridisation onparafﬁn
wax sections was performed as described in Lassiter et al. (2007).
Mouse Ngn1, Ngn2 and SCG10, and chicken Ngn2, were kind gifts
of David Anderson (Caltech, Pasadena, USA). Chicken Pax2 was a kind
gift of Dr. Andrea Streit (King's College London, UK). A 400 bp
fragment of chicken (Gallus gallus) FGFR4 cDNA, corresponding tobase-pairs 54–454 of chicken FGFR4 (GenBank accession number
AF083063), was PCR-ampliﬁed from a cDNA library of homogenised
3–10 somite-stage chick embryos using degenerate primers (5′-
GGAGATGGAGCCAGACTCG-3′ and 5′-ACCTCTCCAGCACRTCCA-3′) and
cloned into the pGEM-T easy vector (Promega).
Immunohistochemistry and confocal microscopy
The following primary antibodies were used: GFP (rabbit;
Molecular Probes/Invitrogen); Islet1 (mouse IgG2b; Developmental
Studies Hybridoma Bank: DSHB), NeuN (mouse IgG1; Chemicon), Pax2
(rabbit; Zymed/Invitrogen), Pax3 (mouse IgG2a; kind gift of Marianne
Bronner-Fraser, Caltech, Pasadena; also available from the DSHB), TuJ1
(mouse IgG2a; Covance/Invitrogen). The Developmental Studies
Hybridoma Bank was developed under the auspices of the NICHD
and is maintained by the University of Iowa, Department of Biological
Sciences, Iowa City. Appropriately matched Alexa488- or Alexa594-
conjugated goat anti-mouse or goat anti-rabbit secondary antibodies,
and Alexa350-NeutrAvidin, were obtained from Molecular Probes/
Invitrogen; biotinylated goat anti-mouse secondary antibodies were
obtained from Southern Biotech.
Immunohistochemistry on sections was performed as described in
Lassiter et al. (2007). The whole-mount immunostaining protocol for
mouse embryos was modiﬁed from Guris et al. (2001). Serial sagittal
images of TuJ1-immunostained mouse embryo heads were collected
to a depth of about 200 μm (2. 8 μm spacing) using an inverted laser
scanning LEICA DM IRBE confocal microscope. Composite images
showing the maximum intensity projection of the stack were
prepared using ImageJ software (National Institutes of Health).
Electroporation constructs
All constructs were prepared using an Endotoxin-free Maxi
preparation kit (Qiagen) according to the manufacturer's instructions
and used at 5.0 μg/μl. The mPax3En-nGFP electroporation construct
was made in the pCIG vector (Megason and McMahon, 2002). It
encodes the ﬁrst 374 amino acids of mouse Pax3 fused to the Droso-
phila Engrailed repressor domain (Bajard et al., 2006; Relaix et al.,
2006), with IRES-nuclear localised green ﬂuorescent protein (GFP).
The empty pCIG vector, encoding nuclear GFP only (nGFP), was used
for control electroporations.
The cPax3/GFP construct was made by inserting full-length chicken
Pax3 cDNA (Matsunaga et al., 2001) into amodiﬁed version of the pCL-
GFP electroporation vector (Scaal et al., 2004), in which the CMV
promoter and associated intron sequence were replaced with the RSV
promoter sequence from pRc/RSV (Invitrogen). GFP expression from
this construct is under the separate control of the SV40 promoter. The
empty vector (GFP) was used for control electroporations.
In ovo electroporation
Fertilised chicken (Gallus gallus) eggs from local farms were
incubated in a humidiﬁed atmosphere at 38 °C until the desired
stage. Black ink (Fount India, Pelikan) was diluted to 10–20% in
Howard Ringer's solution and injected beneath the blastoderm to
visualise the embryo. Electroporation constructs (5.0 μg/μl) were
introduced into surface ectoderm by in ovo electroporation as
described in Lassiter et al. (2007).
Results
Pax3 is necessary for normal neuronal differentiation in the mouse
ophthalmic trigeminal (opV) placode
In both chick and mouse, trigeminal placode-derived neurons
differentiate long before neural crest-derived neurons (Verwoerd and
316 C.M. Dude et al. / Developmental Biology 326 (2009) 314–326van Oostrom, 1979; D'Amico-Martel and Noden, 1980; Nichols, 1986;
Covell and Noden,1989;Moody et al., 1989; Stainier and Gilbert,1990).
Hence, one way to distinguish between Pax3 function in opV placode-
derived neurons versus trigeminal neural crest-derived neurons is to
examine neuronal differentiation in Splotch (Pax3-deﬁcient) embryos
at a stage when only placode-derived neurons have differentiated.
Cells begin delaminating from the mouse trigeminal placodes at E9
(10–12 somite-stage [ss]); almost all delamination is completed by
E10 (30ss) (Nichols, 1986). The ﬁrst placode-derived neurons
differentiate at E9 (14ss), while a second wave of neurogenesis,
presumed to be neural crest-derived, is seen from E10 (30ss), lasting
for 2 days (Stainier and Gilbert, 1990).
We performed whole-mount TuJ1 immunostaining to detect
neuronal beta-III tubulin in wildtype and homozygous Splotch2H
(Sp2H) embryos at E9 (17–18ss), when only placode-derived neurons
have differentiated (Figs. 1A–D). Neurons in the ophthalmic lobe of
the trigeminal ganglion are missing in Sp2H/Sp2H embryos at this
stage (Figs. 1C, D). Hence, Pax3 is necessary for the differentiation of
opV placode-derived neurons. Expression of the proneural basic
helix-loop-helix transcription factor Neurogenin1 (Ngn1) (Ma et al.,Fig. 1. Pax3 is necessary for normal neuronal differentiation of mouse ophthalmic trigeminal
have differentiated, neuronal beta-III tubulin expression (detected by the TuJ1 antibody) sho
towards the eye in a 17-somite wildtype embryo (green channel only in panel A; green chann
panels A1, B1), but absent in a 17-somite homozygous Splotch2H (Sp2H) embryo (green chann
images of the same embryo in C1, D1). The same difference in phenotype was also seen at th
the trigeminal ganglion (arrowheads) in both wildtype (E) and homozygous Sp2H embryos
ophthalmic lobe of the trigeminal ganglion (white arrowheads) and along the ophthalmic n
also, though in reduced numbers, in homozygous Sp2H embryos (H). The lefthand trigeminal
arch; ss, somite-stage.1998) in Sp2H/Sp2H embryos, however, was essentially indistinguish-
able from wildtype, both at E9 (Figs. 1E, F) and also at E8.5 and E9.5
(data not shown). Thus, in Sp2H/Sp2H embryos at E9, opV placode-
derived Ngn1+ neuronal precursors are present (Fig. 1F) but fail to
differentiate as neurons (Figs. 1C, D). By late E9.5 (28ss), expression
of the neuronal marker SCG10 (Anderson and Axel, 1985) revealed
some recovery of neuronal differentiation in the ophthalmic lobe
of Sp2H/Sp2H embryos, though this was still reduced relative to
wildtype (Figs. 1G, H).
Activation of Pax3 target genes is necessary for chick opV placode
development
To investigate the requirement for Pax3 speciﬁcally during opV
placode development, and to test the hypothesis that Pax3 acts as a
transcriptional activator in the opV placode, we used an electro-
poration construct, mPax3En-nGFP, encoding a fusion protein
between mouse Pax3 and the Drosophila Engrailed repressor
(mPax3En) and nuclear GFP. mPax3En retains both Pax3 DNA-
binding domains and has been shown to repress Pax3 target genes(opV) placode cells. (A–D) At embryonic day 9 (E9), before neural crest-derived neurons
ws neurons in the ophthalmic lobe of the trigeminal ganglion (arrowheads) projecting
el superimposed on brightﬁeld in panel B; higher-power images of the same embryo in
el only in panel C; green channel superimposed on brightﬁeld in panel D; higher-power
e 18-somite-stage (not shown). (E, F) At E9, Ngn1 is expressed in the ophthalmic lobe of
(F). (G, H) At late E9.5, expression of the neuronal marker SCG10 shows neurons in the
erve projecting towards the eye (black arrowheads), both in wildtype embryos (G), and
ganglion can be seen, out of focus, in both embryos. E, embryonic day; ma, mandibular
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paired domain is 96.9% identical to the chick paired domain at the
amino acid level, while the homeodomain is 100% identical, so we
predicted that this fusion protein should compete for endogenous
Pax3 binding sites and repress Pax3 target genes in the chick
embryo. Electroporating this construct into cranial ectoderm
enabled us to test the cell-autonomous requirement for activation
of Pax3 target genes during the development of opV placode cells.
nGFP was used as a negative control.
We electroporated either mPax3En-nGFP or nGFP into the cranial
ectoderm of 4–7ss chick embryos, ﬁxed the embryos 24 h later at
the 19–26ss, and performed in situ hybridisation on sections for the
chick opV placode markers ﬁbroblast growth factor receptor 4
(FGFR4; Marcelle et al., 1994; Stark et al., 1997) or Neurogenin2
(Ngn2; Begbie et al., 2002). Within the chick neurogenic placodes,
FGFR4 is opV placode-speciﬁc (Stark et al., 1997); Ngn2 is initially
opV placode-speciﬁc (Begbie et al., 2002), although by the 27ss it is
also expressed in other placodes (Xu et al., 2008). We then
immunostained the sections for GFP, Pax3, and the Lim-domain
transcription factor Islet1, which is expressed in all trigeminal
neurons and has been extensively used as a deﬁnitive marker for
differentiating trigeminal neurons (Begbie et al., 2002; Fedtsova et
al., 2003; Lassiter et al., 2007; Shiau et al., 2008; Xu et al., 2008).
Islet1 is expressed before Brn3a in the opV placode (Begbie et al.,
2002; Fedtsova et al., 2003; Lassiter et al., 2007; Shiau et al., 2008;
Xu et al., 2008), and delaminating Islet1+ opV placode-derived
neurons are apparently post-mitotic (Begbie et al., 2002). Using a
nuclear neuronal antigen, rather than axonal or cytoplasmic
neuronal antigens, also enabled us to count cells precisely in order
to determine the proportion of mPax3En-nGFP or nGFP-targeted
cells that differentiated as neurons.
We counted all GFP+ cells in the opV placode region of
electroporated embryos to determine the proportion of targeted
cells expressing a particular marker. Since electroporation is mosaic,
the opV placode region could be identiﬁed by the presence of
untargeted cells expressing Pax3, Ngn2 or FGFR4: GFP+ cells were only
counted in sections containing such cells. For statistical purposes, we
counted each opV placode with GFP+ cells as a separate targeting
event; cells were counted across a minimum of 5 placodes from 5
embryos (see Table 1). [The same control cell counts are used here as
for the experiments in Lassiter et al. (2007), in which the effects of
blocking canonical Wnt signalling were investigated by electroporat-
ing dominant negative human TCF4 into the opV placode, followed by
sectioning, in situ hybridisation for FGFR4 or Ngn2, and immunostain-
ing for GFP, Pax3 and Islet1. All these experiments were performed at
the same time.]
Very few mPax3En-nGFP-targeted opV placode cells expressed
either FGFR4 (Figs. 2A, B; compare with Figs. 2C, D) or Ngn2 (Figs. 2E,Table 1
Cell counting data across all embryos electroporated in the opV placode with eithermPax3En
for FGFR4, Ngn2 or Islet1 expression, cell delamination, and expression of Pax3 itself
Marker assayed Construct Age when electroporated/
analysed (ss)
No. opV placode
counted (no. em
FGFR4 mPax3-En 6–7/21–25 7 (5)
nGFP 5–7/20–26 6 (5)
Ngn2 mPax3-En 4–7/19–23 6 (5)
nGFP 4–7/20–26 5 (5)
Islet1 mPax3-En 4–7/21–25 11 (8)
nGFP 4–7/20–26 10 (9)
Cell delam. mPax3-En 4–7/20–26 13 (10)
nGFP 5–7/19–25 11 (10)
Pax3 mPax3-En 4–7/20–26 13 (10)
nGFP 4–7/19–25 11 (10)
The mean and standard error about the mean (S.E.M.) are presented graphically in Fig. 3H.
Abbreviations: delam., delamination; mPax3-En, mPax3En-nGFP; No., number of; S.D., stand
(NB The cell counts are lower for Islet1 than for delamination because the Islet1 immunostF; compare with Figs. 2G, H). The mean percentage/placode of
mPax3En-nGFP-targeted cells that expressed FGFR4 or Ngn2 was
very signiﬁcantly lower than for nGFP-targeted cells (pb0.0005,
Student's t-test; Table 1; Fig. 3H). Hence, activation of Pax3 target
genes is necessary for the expression of both FGFR4 and Ngn2 in the
opV placode, or these genes are directly downstream of Pax3 in these
cells.
Very few mPax3En-nGFP-targeted opV placode cells expressed
Islet1 (Figs. 3A, B; compare with Fig. 3C). The mean percentage/
placode of mPax3En-nGFP-targeted cells that expressed Islet1 was
very signiﬁcantly lower than for nGFP-targeted cells (pb0.005,
Student's t-test; Table 1; Fig. 3H). Similarly, very few mPax3En-nGFP-
targeted opV placode cells delaminated into the mesenchyme (Figs.
2A, B, E, F; Figs. 3A, B; compare with Figs. 2C, D, G, H; Fig. 3C). The
mean percentage/placode of mPax3En-nGFP-targeted cells that dela-
minated into the mesenchyme was very signiﬁcantly lower than for
nGFP-targeted cells (pb0.0005, Student's t-test; Table 1; Fig. 3H).
Hence, activation of Pax3 target genes is necessary for neuronal
differentiation and delamination.
Interestingly, we found that expression of Pax3 itself was also
downregulated in mPax3En-nGFP-targeted cells (Figs. 3A, B; compare
with Fig. 3C), suggesting that Pax3 regulates its own expression in the
opV placode. The mPax3En fusion protein does not seem to be
detected by the anti-Pax3 antibody, which was raised against the C-
terminal region (amino acids 298–481) of quail Pax3 (Venters et al.,
2004): most of the corresponding region in mPax3En has been
replaced by the Engrailed repressor domain. Therefore, we could
detect endogenous Pax3 expression in targeted cells. The mean
percentage/placode of mPax3En-nGFP-targeted cells that expressed
Pax3 was very signiﬁcantly lower than for nGFP-targeted cells
(pb0.0005, Student's t-test; Table 1; Fig. 3H).
We previously showed that blocking canonical Wnt signalling in
the opV placode not only led to the loss of Pax3 expression and
subsequent opV placode differentiation, but also downregulated
expression of the preplacodal marker Eya2 (Lassiter et al., 2007).
Although we did not quantify this, we found that electroporating
mPax3En-nGFP also led to the downregulation of Eya2 in the opV
placode (Figs. 3D, E), suggesting that activation of Pax3 target genes
is required to maintain Eya2 expression in the opV placode. The
slight thickening of the ectoderm usually seen in the opV placode
(slight as compared to the thickening seen in the epibranchial and
otic placodes) also seemed to be absent after blocking Pax3 target
genes (compare mPax3En-nGFP-targeted versus untargeted sides of
the embryo shown in Fig. 2A; compare Fig. 2E with Fig. 2G;
compare mPax3En-nGFP-targeted versus untargeted ectoderm in
Fig. 3A).
Repressing Pax3 target genes did not seem to affect cell survival,
since mPax3En-nGFP-targeted cells expressed nuclear GFP without-nGFP (which represses Pax3 target genes) or nGFP as a control, and assayed a day later
s
bryos)
No. GFP+ cells
counted overall
Mean % GFP+ cells per
placode +ve for marker
S.D. S.E.M.
554 1.6 2.0 0.8
305 26.9 12.3 5.0
801 3.7 2.1 0.9
657 48.5 20.8 9.3
1110 1.1 1.7 0.5
894 14.3 12.5 4.0
1215 3.1 4.0 1.1
962 20.8 12.6 3.8
1215 4.3 4.4 1.2
962 40.8 12.8 3.9
ard deviation; S.E.M., standard error of the mean; ss, somite stage; +ve, positive.
aining did not work on all slides.)
Fig. 2. Repressing Pax3 target genes in the chick ophthalmic trigeminal (opV) placode blocks expression of the opV placode markers FGFR4 and Ngn2. All panels show transverse
sections through the opV placode region of chick embryos a day after electroporating eithermPax3En-nGFP or nGFP at the 4–7 somite-stage. (A, B) MostmPax3En-nGFP-targeted cells
(nuclear GFP, green) do not express FGFR4 (arrowheads show examples). (C, D) Control nGFP-targeted cells (nuclear GFP, green), including cells that have delaminated from the
ectoderm, express FGFR4 (arrowheads show examples). (E, F) Most mPax3En-nGFP-targeted cells (nuclear GFP, green) do not express Ngn2 (arrowheads show examples). (G, H)
Control nGFP-targeted cells (nuclear GFP, green) express Ngn2. Much more extensive Ngn2 expression is seen in controls (compare panels E and G). hb, hindbrain.
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compare with Figs. 2D, H; Fig. 3C). Repressing Pax3 target genes in the
Pax2+ otic and epibranchial placodes (which do not themselves
express Pax3) had a small but statistically insigniﬁcant effect on Pax2
expression, showing that the construct does not indiscriminately
quench gene expression: a day after electroporation at the 7–9
somite-stage, the mean percentage of targeted cells counted withinFig. 3. Repressing Pax3 target genes in the ophthalmic trigeminal (opV) placode blocks neuro
Eya2. Panels A–E show transverse sections through the opV placode region of chick embryos a
placode region can be identiﬁed by the expression in untargeted cells of Pax3 and the opV pla
(nuclear GFP, green) in the opV placode region do not express Pax3 itself (red nuclei) or the n
nuclei inmerged images in panels A4, A5 and B4, B5), and do not delaminate. (C) Control nGFP
Ngn2) express Pax3 (red nuclei), differentiate as neurons (white nuclei in C3 for easier visua
(arrows indicate examples of delaminated nGFP-targeted Pax3+Islet1+ cells). (D, E) MostmPa
the preplacodal marker gene Eya2. Arrows indicate untargeted Eya2+ cells near Eya2-negati
obvious effect on Pax2 expression in the otic vesicle and epibranchial placodes (arrowheads
the mean and s.e.m. of the percentage per opV placode ofmPax3En-nGFP-targeted versus con
(see Table 1 for data). The number above each column indicates the number of opV placodePax2+ otic or epibranchial placode ectoderm that co-expressed Pax2
was 68.8%±10.7 for mPax3En-nGFP (965 cells counted across 2
embryos; Figs. 3F, G), versus 85.2%±6.2 for GFP controls (686 cells
counted across 2 embryos; Figs. 5E, F). This difference is not
statistically signiﬁcant (Student's t-test).
We also attempted to knock down Pax3 expression by electro-
porating ﬂuorescein-tagged anti-Pax3 morpholinos into opV placodenal differentiation, delamination, expression of Pax3 itself and of the preplacodal marker
day after electroporating eithermPax3En-nGFP or nGFP at the 4–7 somite-stage. The opV
code-speciﬁc markers FGFR4 (A) or Ngn2 (B, C). (A, B) MostmPax3En-nGFP-targeted cells
euronal differentiation marker Islet1 (white nuclei in A3,B3 for easier visualisation; blue
-targeted cells (nuclear GFP, green) in the opV placode region (identiﬁed by expression of
lisation; blue nuclei in merged images in C4, C5), and delaminate into the mesenchyme
x3En-nGFP-targeted cells (nuclear GFP, green) in the opV placode region do not express
ve mPax3En-nGFP-targeted ectoderm. (F, G) mPax3En-nGFP (nuclear GFP, green) has no
indicate examples of Pax2+ mPax3En-nGFP-targeted cells). (H) Summary graph showing
trol nGFP-targeted cells expressing FGFR4, Ngn2, Islet1, and Pax3 itself, and delaminating
s counted for that case. hb, hindbrain; opV, ophthalmic trigeminal; ov, otic vesicle.
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u?/ETD,590). This consistently reduced or eliminated expression of
opV placode markers, in general agreement with the results shownhere, but it was difﬁcult to identify targeted cells on sections, and
control morpholinos did not always yield consistent results (data not
shown).
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neurons do not differentiate
We investigated whether mis-expression of Pax3 was sufﬁcient to
direct opV placode development in non-opV placodal head ectoderm,
including ectoderm fated to form other placodes, such as the Pax2+
otic and epibranchial placodes (Baker and Bronner-Fraser, 2000). Note
that at early somite stages (at least up to the 4 somite-stage), all cranial
ectoderm rostral to the ﬁrst somite expresses preplacodal marker
genes such as Six4, Eya2 and Dach1 (Litsiou et al., 2005). A day after
electroporating cPax3/GFP (encoding full-length chick Pax3 and GFP
under separate promoters) unilaterally into head ectoderm from the
level of the midbrain to the third somite in 3–10ss embryos, 82% of
targeted embryos (41/50; Figs. 4A–C) showed widespread ectopic
expression of FGFR4 after whole-mount in situ hybridisation, including
in the otic vesicle and pharyngeal arch ectoderm, where the
epibranchial placodes form (Figs. 4A–C). No ectopic FGFR4 expression
was seen after electroporating GFP (0/8 embryos; Fig. 4D).
We quantiﬁed the upregulation of FGFR4 in the Pax2+ otic/
epibranchial placode region by performing in situ hybridisation and
immunostaining directly on sections of ﬁve additional embryos
(Figs. 4E, F; Table 2). Only Pax3+ cells located within a larger Pax2+
domain were included in the dataset. A day after electroporating
cPax3/GFP, the mean percentage/embryo of cPax3/GFP-targeted cells
that clearly expressed FGFR4 above background in the Pax2+ otic/
epibranchial placode region was 27.6% (Table 2). In contrast, in ﬁve
control embryos (electroporated at the 7–8ss and ﬁxed a day later at
the 23–29ss), GFP-targeted cells in otic/epibranchial placode region
ectoderm did not obviously upregulate FGFR4 expression above
background (Fig. 4G).
At the stages analysed, Ngn2 is normally expressed in the
neurogenic region of the otic vesicle and in the epibranchial placodes
(Xu et al., 2008); this normal expression was seen after in situ
hybridisation and immunostaining on sections of ﬁve control embryos
(electroporated with GFP at the 7–8ss and ﬁxed a day later at the 23–
29ss) (Fig. 4H). A day after electroporating cPax3/GFP, the mean
percentage/embryo of cPax3/GFP-targeted cells that expressed Ngn2
in the Pax2+ otic/epibranchial placode region was 32.4% (Figs. 4I, J;
Table 2). Hence, Pax3 induces Ngn2 as well as FGFR4, and in a similar
proportion of targeted cells (Table 2).
We co-immunostained the sections analysed for FGFR4 and Ngn2
expression with Islet1, to detect differentiating neurons. Rather
surprisingly, only 0.85% of the 3167 cPax3/GFP-targeted cells counted
clearly expressed Islet1. The mean percentage/embryo of cPax3/GFP-
targeted cells that expressed Islet1 in the Pax2+ otic/epibranchial
placode region was only 1.7% (Table 2). We also analysed expression
of the neuron-speciﬁc nuclear protein NeuN (Mullen et al., 1992) in
three embryos ﬁxed a day after electroporation at the 12–19ss. In
these older embryos, the epibranchial placodes were identiﬁed by
morphology and position, rather than by Pax2 expression. The mean
percentage/embryo of cPax3/GFP-targeted cells that expressed NeuN
in the epibranchial placode region was only 3.1% (Table 2). In
another embryo, electroporated at the 16ss and incubated for 36 h
(to stage 20; Hamburger and Hamilton, 1951) to allow a longer
time-period for differentiation, we found a cluster of NeuN-negative
cPax3-targeted cells that had delaminated from the epithelium and
were associated with, though excluded from, the NeuN+ geniculate
ganglion (Figs. 4K, L). Overall, these results suggest that although a
subset of cPax3-targeted cells in the otic/epibranchial placode region
expresses Ngn2 and FGFR4, very few differentiate as neurons.
Pax3 is sufﬁcient to alter the identity of otic and epibranchial
placode cells
Strikingly, the mean percentage/embryo of Pax3+ cells in the
otic/epibranchial placodes that co-expressed Pax2 was only 6.2%(Figs. 5A–D; Table 2), versus 85.2%±6.2 for GFP controls (686 cells
counted across 2 embryos; Figs. 5E, F). Furthermore, when otic-level
ectoderm was extensively targeted with cPax3/GFP, otic vesicle
closure was often disrupted (Figs. 5C, D), when compared with the
normal otic vesicle development seen after electroporating GFP into
otic-level ectoderm (Figs. 4G, H).
Overall, therefore, Pax3 mis-expression in otic and epibranchial
placode ectoderm not only upregulates the opV placode markers
FGFR4 and Ngn2, but also downregulates and/or prevents Pax2
expression and disrupts otic vesicle closure, suggesting that Pax3
expression is sufﬁcient to alter the identity of otic and epibranchial
placode cells.
Discussion
Pax3 is necessary for normal neuronal differentiation in the mouse
opV placode
The Splotch2H (Sp2H) mutation is a 32-basepair deletion in the
Pax3 homeobox, yielding a truncated protein lacking the whole of
the C-terminal transactivation domain and part of the home-
odomain (Epstein et al., 1991). The Sp2H phenotype is indistin-
guishable from the original Splotch allele (in which genomic
mutations in intron 3 prevent normal splicing; Epstein et al.,
1993), and both are considered functionally null alleles (Epstein et
al., 1991, 1993). We found that at E9, before mouse neural crest-
derived trigeminal neurons have differentiated (Verwoerd and van
Oostrom, 1979; Nichols, 1986; Stainier and Gilbert, 1990), opV
placode-derived neurons in the developing ophthalmic lobe of the
trigeminal ganglion are missing in homozygous Sp2H embryos,
although the proneural transcription factor Ngn1 is expressed
normally. Hence, in the absence of wildtype Pax3 function, Ngn1+
opV placode cells fail to differentiate as neurons. At late E9.5, we
saw some recovery of neuronal differentiation in the ophthalmic
lobe and along the ophthalmic nerve projection towards the eye. It
is possible that these neurons are derived from early-differentiat-
ing trigeminal neural crest cells, or even that they represent a
rostral expansion of maxillomandibular trigeminal placode-derived
neurons.
Activation of Pax3 target genes is necessary for chick opV
placode development
We tested the cell-autonomous requirement for activation of
Pax3 target genes during the development of the chick opV placode
by electroporating a construct encoding a fusion between mouse
Pax3 and the Drosophila Engrailed repressor domain (previously
shown to repress Pax3 target genes in the mouse; Bajard et al.,
2006; Relaix et al., 2006). We found that activation of Pax3 target
genes is necessary for expression of the opV placode markers FGFR4
and Ngn2, maintenance of Pax3 itself and of the preplacodal marker
gene Eya2, expression of the neuronal differentiation marker Islet1,
and delamination. We also found that the normal slight thickening
seen in the opV placode (slight as compared to the much thicker
ectoderm of the otic and epibranchial placodes) seemed to be lost
after blocking Pax3 target gene expression. Hence, activation of Pax3
target genes is necessary for all aspects of chick opV placode
development. These results also conﬁrm that Pax3 acts as a
transcriptional activator in the opV placode, as it does in the neural
tube, neural crest and somites (Relaix et al., 2003; Bajard et al.,
2006).
We previously found that blocking canonical Wnt signalling in
opV placode ectoderm led to the loss of Pax3 expression and the
failure of opV placode development, including expression of FGFR4,
maintenance of Eya2, neuronal differentiation (as assayed by Islet1,
NeuN and neuroﬁlament expression) and delamination (Lassiter et
Fig. 4. Pax3mis-expression is sufﬁcient to induce FGFR4 and Ngn2 expression in non-opV placode head ectoderm. (A–C) Ectopic FGFR4 expression is seen in head ectoderm a day after
electroporating cPax3/GFP on the righthand side (black arrowheads), including in the otic vesicle (ov) and nearby pharyngeal ectoderm,where the epibranchial placodes form. Normal
FGFR4 expression is seen in the opV placode on the unelectroporated side (white arrowhead) and in the lens (Marcelle et al.,1994). Panels A and B show two different embryos; panel C
shows a transverse section through another embryo after whole-mount in situ hybridisation for FGFR4. (D) No ectopic FGFR4 expression is seen after electroporating GFP; normal
FGFR4 expression is seen in the lens and opV placode (white arrowhead). (E, F) In situ hybridisation directly on sections shows strong FGFR4 expression in cPax3/GFP-targeted cells
(Pax3, red nuclei) in the epibranchial placode region, a day after electroporation at the 6–7 somite-stage. (This is a different embryo from those shown in panels A–C.) (G) FGFR4
expression is not seen in GFP-targeted cells (cytoplasmic GFP, green) in the otic and epibranchial placode region, a day after electroporation at the 7–8 somite-stage. (H) Normal Ngn2
expression is seen inGFP-targeted cells (cytoplasmic GFP, green) in the otic and epibranchial placode region, a day after electroporation at the 7–8 somite-stage. (I, J)Ngn2 expression is
seen in cPax3/GFP-targeted cells (Pax3, red nuclei) in surface ectoderm in the vicinity of the otic vesicle, a day after electroporation at the 6–7 somite-stage. (K, L) The neuronal nuclear
protein NeuN (red nuclei) is expressed in the vestibuloacoustic and geniculate ganglia, but not in a cluster of cPax3/GFP-targeted cells (Pax3, blue nuclei; GFP, green cytoplasm) at the
edge of the geniculate ganglion, 36 h after electroporation at the 16ss. gen, geniculate ganglion; h, heart; hb, hindbrain; ov, otic vesicle; va, vestibuloacoustic ganglion.
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necessary for all of these events, suggesting that the effects of
blocking canonical Wnt signalling are at least partly due to the loss
of Pax3 expression.Pax3 autoregulates in the opV placode
Since activation of Pax3 target genes is needed to maintain Pax3 in
the opV placode, this suggests that Pax3 regulates its own expression.
Table 2
Cell counting data across all embryos electroporated in otic/epibranchial placode
ectoderm with cPax3/GFP and assayed a day later for FGFR4, Ngn2, Islet1, NeuN or Pax2
expression
Marker
assayed
Age when
electroporated
with cPax3/GFP/
analysed (ss)
No.
embryos
No. cPax3/
GFP-targeted
cells counted
overall
Mean %/embryo
of cPax3/GFP-
targeted cells +ve
for marker
S.D. S.E.M.
FGFR4 6–7/23–28 5 1296 27.6 22.9 10.2
Ngn2 7–8/21–26 4 2148 32.4 6.2 3.1
Islet1 6–8/21–28 8 3167 1.7 2.9 1.0
NeuN 12–19/26–36 3 430 3.1 3.4 2.0
Pax2 6–8/21–28 9 3444 6.2 5.5 1.8
Abbreviations: No., number of; S.D., standard deviation; S.E.M., standard error of the
mean; ss, somite stage; +ve, positive.
(NB The cell counts and embryo numbers are lower for Islet1 than for Pax2 because the
Islet1 immunostaining did not work on slides from one embryo.)
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sufﬁcient to drive skeletal (but not cardiac) myogenesis, in vitro
experiments using a similar Pax3–Engrailed fusion protein (in this
case between the ﬁrst 286 amino acids of Pax3 and the mouse
Engrailed2 repressor domain) have also shown that activation of Pax3
target genes is required for Pax3 expression (Ridgeway and Skerjanc,Fig. 5. Pax3 mis-expression in epibranchial and otic placode ectoderm downregulates Pa
epibranchial placode and/or otic vesicle region of chick embryos either 1 day (A–F) or 2 days
GFP-targeted cells (Pax3, red nuclei) in the epibranchial placode region do not co-express Pa
panel B show Pax3+Pax2-negative cells; yellow arrowheads show Pax3+Pax2+ cells. (C, D) M
Ngn2, fail to co-express Pax2 (green nuclei), and the otic vesicle fails to close properly (compar
arrowheads show Pax3+Pax2+ cells. (E, F) Electroporating GFP (cytoplasmic GFP, green) ha
examples of Pax2+GFP+ cells. (NB All these embryos were ﬁxed for in situ hybridisation on w
procedure, and the anti-Pax2 antibody was also raised in rabbit, for the GFP controls we perfo
ov, otic vesicle; ph, pharynx.2001). There is precedent for direct autoregulation of Pax genes: Pax6
positively autoregulates in the lens and cornea by directly binding a
head ectoderm-speciﬁc enhancer in the Pax6 gene (Ashery-Padan et
al., 2000; Aota et al., 2003), and in the diencephalon by binding to a
conserved enhancer in intron 7 of the Pax6 gene (Kleinjan et al., 2004).
Interestingly, Pax6 also negatively autoregulates at high levels: over-
expression of Pax6 protein leads to the downregulation of Pax6
expression (Manuel et al., 2007).
Pax3 upregulates FGFR4 and Ngn2 expression in head ectoderm
Both FGFR4 and Ngn2 are expressed in the chick opV placode from
the 10ss (Stark et al., 1997; Begbie et al., 2002), a few hours after Pax3
protein ﬁrst becomes detectable by immunostaining, at the 8–9ss
(Baker et al., 1999). We found that Pax3 mis-expression in non-opV
placode head ectoderm, including the otic and epibranchial placodes,
upregulates FGFR4 and Ngn2 in a subset of targeted cells. In the
mouse, FGFR4 and Ngn2 were recently shown to be direct transcrip-
tional targets of Pax3 (Lagha et al., 2008; Nakazaki et al., 2008), so it is
possible that Pax3 directly activates both genes during chick opV
placode development. In the mouse, we found that Pax3 is not
necessary for Ngn1 expression in the opV placode. However, the
expression of Ngn1 and Ngn2 is different in mouse and chickx2 and disrupts otic vesicle closure. All panels show transverse sections through the
(G–J) after electroporating cPax3/GFP or GFP at the 6–8 somite-stage. (A, B) Most cPax3/
x2 (green nuclei). Compare with unelectroporated side in panel A. White arrowheads in
ost cPax3/GFP-targeted cells (Pax3, red nuclei) in the otic vesicle, as well as expressing
ewith Figs. 4G, H).White arrowheads in panel D show Pax3+Pax2-negative cells; yellow
s no effect on Pax2 expression in the epibranchial placodes: white arrowheads show
ax sections. Since only the rabbit anti-GFP antibody works well in our hands after this
rmed in situ hybridisation for Pax2, followed by immunostaining for GFP.) hb, hindbrain;
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mmV placodes (Gradwohl et al., 1996; Sommer et al., 1996; Fode et al.,
1998; Ma et al., 1998), with Ngn2 only transiently expressed later in
what appears to be (though was not reported as such) speciﬁcally the
opV placode (Fode et al., 1998). In the chick trigeminal placodes, Ngn2
is speciﬁcally expressed in the opV placode, at least initially (Xu et al.,
2008), whileNgn1 is only expressed in themmV placode (Begbie et al.,
2002). It is not clear what changes in gene regulation have led to this
difference between mouse and chick (Furlong and Graham, 2005).
The absolute levels of Pax3 are important for its function
It is striking that only aminority of targeted ectoderm cells (around
30%) expressed FGFR4 or Ngn2 following Pax3 mis-expression. One
possibility that could be considered is the importance of absolute Pax3
expression levels for the activation of gene expression. Heterozygous
mutations in Pax3 have a phenotype primarily due to defects in
melanocyte development (pigmentation defects in mice, pigmentary–
auditory deﬁcits in human Waardenburg syndrome I or III), while it
was recently shown that Pax3 hypomorphs have deﬁcits in limb and
hypoglossal (but not other hypaxial or epaxial) musculature (Zhou et
al., 2008). Thus, the absolute levels of Pax3 are critical for the
appropriate development of speciﬁc subpopulations of Pax3-expres-
sing cells. Furthermore, in vitro experiments have shown that low
levels of Pax3 activate expression of a reporter construct, while higher
levels inhibit its expression (Chalepakis et al., 1994). The change from
activation to inhibition occurred over a relatively narrow concentra-
tion range: a 2-fold increase in concentration was enough for the
switch (Chalepakis et al., 1994). When Pax3 is mis-expressed outside
opV placode ectoderm, each electroporated cell is likely to receive a
different amount of plasmid, and thus be exposed to different levels of
Pax3 expression. One could speculate that only cells where Pax3 levels
arewithin a particular range are likely to activate (rather than repress)
expression of Ngn2, FGFR4, and other direct or indirect Pax3 gene
targets. However, although we did not quantify Pax3 levels after mis-
expression, a qualitative analysis shows that both cells with very
bright and cells with relatively faint levels of Pax3 immunoﬂuores-
cence upregulated FGFR4 or Ngn2 (e.g. Figs. 4F, J).
Pax3 mis-expression does not promote neuronal differentiation
Although Pax3 target gene activation is necessary for neuronal
differentiation in the opV placode, and Ngn2 is upregulated in a subset
of Pax3-targeted cells in non-opV placode head ectoderm, the great
majority of these cells do not differentiate as neurons. Retroviral-
mediated mis-expression of Ngn2 in the chick embryo leads to ectopic
sensory neurogenesis in neural crest cell derivatives and the
dermomyotome (Perez et al., 1999). However, we found in previous
experiments that blocking canonical Wnt signalling in either trunk or
head ectoderm broadly upregulates Ngn2 expression without any
accompanying neuronal differentiation (Lassiter et al., 2007). Indeed,
Ngn2 may be more important for specifying neuronal subtypes than
for directly promoting neuronal differentiation: genetic lineage-
tracing has shown that Ngn2 expression biases (but does not commit)
mouse trunk neural crest cells to a sensory fate (either neuronal or
glial) (Zirlinger et al., 2002). Similarly, genetic experiments in which
the coding sequences for Mash1 and Ngn2 were swapped suggested
that Ngn2 acts permissively, rather than instructively, to specify
neuronal phenotype in combination with other transcription factors
(Parras et al., 2002).
The failure of Pax3-targeted cells to differentiate as neurons
suggests that additional signals are required for neuronal differentia-
tion, and/or that the maintenance of high levels of Pax3 expression
blocks subsequent neuronal differentiation. In myogenesis, FGFR4,
which is expressed after Pax3, is required for chick muscle
differentiation and mouse muscle regeneration (Marics et al., 2002;Zhao et al., 2006). Hence, signalling through FGFR4 seems to be
necessary for a Pax3+ muscle cell to differentiate. It is possible that
FGFR4 plays a similar role in the opV placode, i.e., that only Pax3+
cells in which signalling through FGFR4 has been activated are able to
differentiate as neurons. Various different FGFs are known to activate
FGFR4 (Ornitz et al., 1996; Zhang et al., 2006). If the appropriate ligand
(s) is not present in the targeted region, then even FGFR4+ Pax3-
targeted cells may not differentiate as neurons.
There is increasing evidence that Pax3 can both activate expression
of genes required for a speciﬁc differentiation pathway, and block
differentiation until appropriate signals are received that down-
regulate Pax3 expression levels or activity. Pax3 activates myelination
genes, and its expression in Schwann cell precursors is downregulated
immediately prior to terminal differentiation (Kioussi et al., 1995).
Enforced maintenance of Pax3 expression in neural crest cells blocks
neural crest-derived osteoblast differentiation (Wu et al., 2008). In
melanocytes, Pax3 initiates differentiation by activating MITF tran-
scription, but blocks differentiation until beta-catenin displaces Pax3-
recruited Grg4 from the dopachrome tautomerase promoter (Lang et
al., 2005). Transfecting antisense Pax3 RNA into the undifferentiated
neuronal cell line ND7 results in differentiation, suggesting that Pax3
blocks neuronal differentiation in this cell line (Reeves et al., 1999).
Antisense-oligonucleotide downregulation of Pax3 in neural crest
cultures inhibits sensory neuron differentiation without affecting
survival of sensory neurons or precursor populations (Koblar et al.,
1999), and neural crest cells undergo premature neurogenesis in
Splotchmice (Nakazaki et al., 2008). Although Pax3 is not expressed in
neural crest-derived neurons in either the trigeminal or dorsal root
ganglia, it is expressed in non-neuronal neural crest cells in these
ganglia, albeit at much lower levels than in opV placode-derived cells
(Baker et al., 2002). This suggests that Pax3must be downregulated as
soon as (or before) neural crest cells differentiate as neurons. Similarly,
in spinal cord neurogenesis, Pax6 upregulates Ngn2, which promotes
cell cycle exit and neuronal commitment, but the cells do not
differentiate as neurons until Pax6 is itself repressed by increasing
levels of Ngn2 (Bel-Vialar et al., 2007).
How might this model apply to Pax3+ opV placode-derived
neurons, which maintain high levels of Pax3 expression long after
differentiation in the chick (Baker et al., 2002)? Interestingly, in the
neuronal cell line ND7, the DNA-binding activity of Pax3 is down-
regulated within an hour of the induction of neuronal differentiation,
before any drop in Pax3 expression levels can be detected (Reeves et
al., 1998). Phosphorylation of the linker region between the paired
domain and homeodomain of Pax3 inhibits DNA binding without
affecting nuclear localisation or stability (Amstutz et al., 2008). Thus, it
is possible that in normal opV placode development, neuronal
differentiation only occurs when the DNA-binding activity of Pax3 is
inhibited, perhaps by phosphorylation of the linker region in response
to an extracellular or intracellular signal. If this signal were only
present in the opV placode, this model might explain why Pax3+
ectodermal cells outside the opV placode do not differentiate as
neurons, even when FGFR4 and Ngn2 are expressed. Alternatively,
high levels of Pax3 after mis-expression might swamp the protein-
modiﬁcation machinery, short-circuiting the neuronal differentiation
pathway.
Pax3 is sufﬁcient to alter the identity of otic and epibranchial
placode cells
After Pax3 mis-expression in the Pax2+ otic and epibranchial
placodes, very few targeted cells co-express Pax2. Since Pax2 should
have been expressed at the time of electroporation (6–8ss; Groves and
Bronner-Fraser, 2000; Streit, 2002), this suggests that Pax3 mis-
expression downregulates Pax2. This is reminiscent of the mutual
repression seen between Pax2 and Pax6 in the mammalian eye that
establishes the optic cup/optic stalk boundary (Schwarz et al., 2000).
Fig. 6.Model for opV placode development in the chick embryo, based onwork presented here and in Lassiter et al. (2007), as well as McCabe and Bronner-Fraser (2008). See text for
details. fb, forebrain; ov, otic vesicle.
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can repress Pax6 expression, while Pax6 can repress Pax2 transcrip-
tion, as well as activate its own transcription (Schwarz et al., 2000).
Furthermore, Pax3 mis-expression in the otic and epibranchial
placodes induces expression of the opV placode-speciﬁc marker
FGFR4 and upregulates Ngn2, and disrupts closure of the otic vesicle.
Overall, these experiments show that Pax3 can change the fate of
other placodal cells, suggesting that it is important for placodal cell
identity.
Model for opV placode development in the chick embryo
At the 3-somite stage, all cranial ectoderm rostral to the ﬁrst
somite is competent to respond to a Pax3-inducing signal from the
dorsal neural tube (though competence is rapidly lost by speciﬁed otic
placode ectoderm) (Stark et al., 1997; Baker et al., 1999). This region of
competence correlates with expression of the preplacodal marker
genes Six4, Eya2 and Dach1 (Litsiou et al., 2005). Both canonical Wnt
signalling (Lassiter et al., 2007) and PDGF signalling from the neural
folds (McCabe and Bronner-Fraser, 2008) are necessary for Pax3
expression in the opV placode and subsequent opV placode develop-
ment, but neither is sufﬁcient to induce Pax3 in competent ectoderm
(Lassiter et al., 2007; McCabe and Bronner-Fraser, 2008). FGF
signalling from the neural folds is a likely additional candidate; this
is under investigation. Canonical Wnt signalling may serve to stabilise
Pax3 expression, since it is required not only for Pax3 expression but
also for its maintenance (Lassiter et al., 2007). Thus, we propose a
model in which Pax3 expression is stabilised in those Pax3+ cells that
receive canonical Wnt signals (just as, in the otic placode, canonical
Wnt signals are required for Pax2+ cells to adopt an otic rather than
epidermal fate; Ohyama et al., 2006). Activation of Pax3 target genes,
directly or indirectly, is necessary for the expression of FGFR4 and
Ngn2, to maintain expression of Pax3 itself (and the preplacodal
marker gene Eya2), and to enable delamination and neuronal
differentiation. However, additional signals (which may abrogate
Pax3 function) are necessary to enable Pax3+ opV placode cells to
differentiate as neurons. This model is summarised in Fig. 6.
Summary
We have shown that Pax3 is necessary for normal neuronal
differentiation of Ngn1+ opV placode cells in the mouse. In the
chick, we have shown that activation of Pax3 target genes is
necessary for all aspects of opV placode development: expression of
the opV placode markers FGFR4 and Ngn2, maintenance of Pax3itself (suggesting Pax3 autoregulates) and the preplacodal marker
gene Eya2, placodal thickening, neuronal differentiation and dela-
mination. Mis-expression of Pax3 in non-opV placode head
ectoderm is sufﬁcient to induce FGFR4 and Ngn2, downregulate
Pax2 in the otic/epibranchial placodes and disrupt otic vesicle
closure, showing that Pax3 is sufﬁcient to alter the fate of other
placode cells. However, most Pax3-targeted cells in the otic or
epibranchial placodes do not differentiate as neurons. Taken
together, these results support a model in which activation of
Pax3 target genes is necessary for opV placode development,
including neuronal differentiation, but additional signals are
required to enable Pax3+ opV placode cells to differentiate as
neurons. Overall, therefore, Pax3 is necessary but not sufﬁcient for
sensory neurogenesis within the opV placode.
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